Arix Bioscience plc Dr Roberto Iacone appointed as EiR
March 09 2020 - 8:00AM
UK Regulatory
TIDMARIX
Arix Bioscience plc
Arix names Dr Roberto Iacone as Entrepreneur in Residence
New role extends collaboration with Takeda Ventures to identify opportunities
for early stage investment and creation of biotechnology companies
LONDON, 9 March 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture
capital company focused on investing in and building breakthrough biotech
companies today announced the appointment of Dr. Roberto Iacone as Entrepreneur
in Residence ("EiR"). In his new role, Roberto will focus on company creation,
sourcing early stage European investment opportunities that Arix will jointly
fund with its partner, Takeda Ventures, Inc. the strategic venture investing
arm of Takeda Pharmaceuticals.
Roberto has over 15 years' experience in the life sciences sector. He joins
Arix from his role as EiR at Versant Ventures where he was involved in the
successful founding of new companies, including Black Diamond Therapeutics,
where he served as VP Biology. Previously, Roberto was the Director and Global
Head of the Rare Diseases Research Division at Roche, where he was employed for
10 years. During his tenure at Roche, he was responsible for generating disease
area strategies and advancing several assets for immunological and neurological
disease from discovery to early clinical development, which included both large
and small molecule programs. He obtained his MD/PHD from the Max Planck
Institute and University of Naples Federico II.
Joe Anderson, Chief Executive Officer, commented: "I am delighted to welcome
Roberto to the investment team. Roberto brings a wealth of international
experience and excellent track record of creating companies that foster
exciting science. He will be a valuable addition to Arix and Takeda as we work
together to create innovative new companies that address serious medical need."
Mike Martin, Head of Takeda Ventures commented:
"Takeda has a leading partnership model that values external collaboration to
unlock innovation no matter where it resides. My colleagues and I look forward
to working with Roberto and the rest of the team at Arix to identify exciting
opportunities to create early-stage companies that could one day deliver
transformational medicines to patients."
Roberto Iacone commented: "Arix has a superb portfolio of innovative companies
and I am very excited to be working with such an experienced investment team.
The partnership with Takeda is a fantastic opportunity for both companies to
work together to build exciting biotech companies and their respective
pipelines."
Roberto will be the second Entrepreneur in Residence at Arix after Munich based
Christian Schetter, who joined in December 2018. Roberto will be based in
Basel.
[ENDS]
Enquiries
For more information, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3950 9144
optimum.arix@optimumcomms.com
About Arix Bioscience Plc
Arix Bioscience plc is a global venture capital company focused on investing in
and building breakthrough biotech companies around cutting edge advances in
life sciences.
We collaborate with exceptional entrepreneurs and provide the capital,
expertise and global networks to help accelerate their ideas into important new
treatments for patients. As a listed company, we are able to bring this
exciting growth phase of our industry to a broader range of investors.
www.arixbioscience.com
END
(END) Dow Jones Newswires
March 09, 2020 08:00 ET (12:00 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024